Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Mesenchymal Stem Cell Therapy for Aplastic Anemia
ChiCTR2600125907Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Jun 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in aplastic anemia, sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Dose Limiting Toxicity and Incidence of Serious Adverse Events. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2600125907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125907.